Leaderboards/Diabetes, Cardiovascular Risks, and Lipoproteins

Diabetes, Cardiovascular Risks, and Lipoproteins

Last updated July 15, 2026

Rising Stars

Fresh ink, massive impact

Papers

Metabolic score for insulin resistance (METS-IR) predicts all-cause and cardiovascular mortality in the general population: evidence from NHANES 2001–2018

Cardiovascular Diabetology|2024

190 cit.

Publication in American Journal of Preventive Cardiology (2024) [103 citations, W4392906909]

American Journal of Preventive Cardiology|2024

103 cit.

Publication in Cardiovascular Diabetology (2025) [76 citations, W4408295858]

Cardiovascular Diabetology|2025

76 cit.

Excess Apolipoprotein B and Cardiovascular Risk in Women and Men

Journal of the American College of Cardiology|2024

56 cit.

Publication in Nature Medicine (2025) [26 citations, W4414614476]

Nature Medicine|2025

26 cit.

Publication in Cardiovascular Diabetology (2025) [18 citations, W4410547716]

Cardiovascular Diabetology|2025

18 cit.

Identification of Postn+ periosteal progenitor cells with bone regenerative potential

JCI Insight|2024

16 cit.

Publication in Scientific Reports (2025) [13 citations, W4406235379]

Scientific Reports|2025

13 cit.

Publication in BMC Cardiovascular Disorders (2025) [4 citations, W4411982522]

BMC Cardiovascular Disorders|2025

4 cit.

Publication in Journal of Cardiac Failure (2024) [3 citations, W4404343363]

Journal of Cardiac Failure|2024

3 cit.

Emerging Leaders

Drafting the new consensus

Papers

The global burden of metabolic disease: Data from 2000 to 2019

Cell Metabolism|2023

764 cit.

The effect of diabetes and prediabetes on the prevalence, complications and mortality in nonalcoholic fatty liver disease

Clinical and Molecular Hepatology|2022

83 cit.

Mortality trends in type 1 diabetes: a multicountry analysis of six population-based cohorts

Diabetologia|2022

68 cit.

Hypertension is prevalent in non-alcoholic fatty liver disease and increases all-cause and cardiovascular mortality

Frontiers in Cardiovascular Medicine|2022

68 cit.

Type 2 diabetes mellitus in metabolic-associated fatty liver disease vs. type 2 diabetes mellitus non-alcoholic fatty liver disease: a longitudinal cohort analysis

Annals of Hepatology|2022

50 cit.

Elevated plasma triglyceride concentration and risk of adverse clinical outcomes in 1.5 million people: a CALIBER linked electronic health record study

Cardiovascular Diabetology|2022

41 cit.

The Spectrum and Impact of Metabolic Dysfunction in MAFLD: A Longitudinal Cohort Analysis of 32,683 Overweight and Obese Individuals

Clinical Gastroenterology and Hepatology|2022

38 cit.

Development of Alcohol‐Associated Hepatitis Is Associated With Specific Changes in Gut‐Modified Bile Acids

Hepatology Communications|2022

33 cit.

Safety and tolerability of obeticholic acid in chronic liver disease: a pooled analysis of 1878 individuals

Hepatology Communications|2023

31 cit.

Meta‐analysis: analysis of mechanistic pathways in the treatment of <scp>non‐alcoholic</scp> steatohepatitis. Evidence from a Bayesian network <scp>meta‐analysis</scp>

Alimentary Pharmacology & Therapeutics|2022

30 cit.

Current Senior Leaders

Wrote the book, still writing it

Researchers

University of North Carolina at Chapel Hill

Kelly L. Close

Close Concerns (United States)

Peter W.F. Wilson

VA Tennessee Valley Healthcare System

William H. Dietz

George Washington University

Ernst J. Schaefer

Tufts University

Jaakko Tuomilehto

University of Helsinki

Daniel J. Rader

University of Pennsylvania

Ramachandran S. Vasan

The University of Texas at San Antonio Health Science Center

Papers

Harmonizing the Metabolic Syndrome

Circulation|2009

14.7k cit.

International Diabetes Federation 2017

Journal of Diabetes|2018

13.6k cit.

Obesity : Preventing and managing the global epidemic

Research at the University of Copenhagen (University of Copenhagen)|2000

13k cit.

Prevention of Type 2 Diabetes Mellitus by Changes in Lifestyle among Subjects with Impaired Glucose Tolerance

New England Journal of Medicine|2001

10.9k cit.

Prediction of Coronary Heart Disease Using Risk Factor Categories

Circulation|1998

9.6k cit.

The metabolic syndrome—a new worldwide definition

The Lancet|2005

9.3k cit.

Global estimates of the prevalence of diabetes for 2010 and 2030

Diabetes Research and Clinical Practice|2009

7.3k cit.

2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults

Circulation|2013

7.1k cit.

Prevalence of the Metabolic Syndrome Among US Adults

JAMA|2002

6.7k cit.

Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond

Statistics in Medicine|2007

6.3k cit.

Reagents for Diabetes, Cardiovascular Risks, and Lipoproteins

Citation-validated products used in this field

🔥 Trending

Gaining adoption fast

⭐ Top Rated

Best all-around

Cell Signaling TechnologyEvidence 66

Phospho-S6 Ribosomal Protein (Ser240/244) Antibody

Cited in 10 papers

#2215$366

View Evidence →

Cell Signaling TechnologyEvidence 61

AsCpf1/Cas12a (Strain BV3L6) (E1U7C) Rabbit Monoclonal Antibody

Cited in 7 papers

#19984$175,354

View Evidence →

Cell Signaling TechnologyEvidence 68

CD45 (D3F8Q) Feline Chimeric Monoclonal Antibody

Cited in 7 papers

#78406$166,369

View Evidence →

🌟 All-Time

Most validated

Cell Signaling TechnologyEvidence 67

Vimentin (D21H3) Rabbit Monoclonal Antibody (APC Conjugate)

Cited in 21 papers

#95159$465

View Evidence →

Cell Signaling TechnologyEvidence 66

MO25 alpha/CAB39 (C49D8) Rabbit Monoclonal Antibody

Cited in 13 papers

#2716$158,348

View Evidence →

Cell Signaling TechnologyEvidence 65

Stat3 (D1B2J) Rabbit Monoclonal Antibody

Cited in 10 papers

#30835$167,366

View Evidence →